Assenagon Asset Management S.A. Makes New $307,000 Investment in FibroGen, Inc. (NASDAQ:FGEN)

Assenagon Asset Management S.A. bought a new stake in FibroGen, Inc. (NASDAQ:FGEN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 767,663 shares of the biopharmaceutical company’s stock, valued at approximately $307,000.

A number of other large investors have also recently made changes to their positions in the company. Alpine Global Management LLC acquired a new position in FibroGen during the first quarter worth approximately $25,000. Delap Wealth Advisory LLC purchased a new position in shares of FibroGen during the first quarter worth approximately $27,000. Point72 DIFC Ltd increased its holdings in shares of FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the period. Doheny Asset Management CA purchased a new stake in FibroGen in the 2nd quarter valued at $48,000. Finally, Accel Wealth Management boosted its stake in FibroGen by 117.5% during the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 51,645 shares during the period. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Trading Up 5.8 %

FibroGen stock opened at $0.32 on Monday. The stock has a 50 day moving average of $0.37 and a two-hundred day moving average of $0.76. FibroGen, Inc. has a twelve month low of $0.29 and a twelve month high of $2.93. The stock has a market capitalization of $32.02 million, a price-to-earnings ratio of -0.19 and a beta of 0.72.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period in the prior year, the business earned ($0.65) earnings per share. Equities analysts predict that FibroGen, Inc. will post -0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of FibroGen in a report on Tuesday, October 29th. They issued a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.